Atea Pharmaceuticals Inc

In a Stage 3 distribution range, price remains below down-sloping EMAs and the 50 DMA, with rallies failing into resistance and volume contracting on advances. The 3-year uptrend anchors long-term polarity, but medium-term asymmetry favors sellers. Short-term timing offers no clear edge until rallies into the 9/21 EMA zone. Execution should focus on fading strength at these EMAs around the upper boundary of the trading range.

• ↑Phase II trials showed a 98% sustained virologic response.
• ↑Strong $379.7M cash position sustains Phase III through 2027.
• ↓Phase III delays or unfavorable data may stall product approval.